SVRA - Savara Corp Price Target Chart
The price trajectory of Savara Inc. (SVRA) helps assess the commercial launch potential of molgrastim for aPAR therapy, which serves as the basis for future revenue. The current indicator is 11.10. Savara Inc. (SVRA) is developing its distribution infrastructure and international ties without mergers, while outsourcing drug production and trials to third-party contractors to optimize logistics and medication availability.
Analytical breakdowns for Savara Corp (SVRA)
- price and consensus price forecast:
- market capitalization statistics:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Savara Inc.|SVRA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Savara Pharma|SVRA - Company Aggregate Debts|Debts to Book Capitalization Savara Corp|SVRA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Savara|Quick Liquidity Indicator savarapharma.com
- earnings and valuation multiples information:
SVRA - Net Profit|Projected Future Earnings Savara Inc.|SVRA - Price to Earnings Ratio|Future Price to Earnings Multiple Savara Inc|SVRA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Savara Corp|SVRA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Savara|SVRA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months savarapharma.com|SVRA - Net earnings per share growth this year|Earnings growth forecast for next year Savara Inc.
General company analysis:SVRA savarapharma.com
A conservative approach to analyzing Savara Inc. (SVRA) requires comparing market quotes with fundamental value. This indicator represents the arithmetic mean of target prices from independent experts. The trend of the average market target price reflects the speed at which valuations adapt to new data. For Savara Inc. (SVRA), this is critical when assessing the success of joint research into rare lung diseases. The upward curve confirms market optimism regarding the efficacy of the implemented therapies.
Competitors of Savara Inc.
Analyst Median Target argenx.com|BioNTech - Consensus Target|Abivax SA - Price Target Chart|ADMA - Price Target Chart|Fair Value Consensus PTGX (Protagonist Corp)|IMVT: Analyst Consensus Forecast|kiniksa.com (KNSA) - Analyst Consensus Forecast|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|ACRS - Price Target Chart|Analyst Median Target Kyverna Therapeutics, Inc KYTX|TLSA: Analyst Consensus Forecast|cabalettabio.com (CABA) - Analyst Consensus Forecast|Consensus Target VTYX|Price Target Chart THTX|Analyst Consensus Forecast AVTX|Analyst Consensus Forecast Eledon Pharmaceuticals, Inc (ELDN)|Price Target Chart Agenus AGEN|Fair Value Consensus CLYM|Zura Bio Limited - Analyst Consensus Forecast|ATYR - Analyst Consensus Forecast|ADAG (adagene.com) - Consensus Target|Ikena Oncology - Fair Value Consensus|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Equillium Bio (EQ) - Analyst Median Target|Price Target Chart Connect Biopharma (CNTB)|immunic-therapeutics.com - Broker Consensus Forecast|Analyst Consensus Forecast ATRA (Atara Bio)|IFRX - Consensus Target|XFOR: Consensus Target|Analyst Median Target Adicet Bio ACET|celularity.com (CELU) - Price Target Chart|INMB - Analyst Median Target|Consensus Target BRNS|Price Target Chart KZR|Price Target Chart SAB Biotherapeutics (SABS)|AKTX (akaritx.com) - Fair Value Consensus|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Analyst Consensus Forecast Q32 Bio Inc QTTB|GOVX - Price Target Chart|Forecast Levels Chart EDSA|IBIO: Analyst Consensus Forecast|Carisma Therapeutics Inc. - Fair Value Consensus|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Analyst Consensus Forecast Bolt Bio|Price Target Chart HCW Biologics Inc. (HCWB)|APVO (aptevotherapeutics.com) - Fair Value Consensus|Price Target Chart AIM ImmunoTech AIM|ADTX - Consensus Target|GRI Bio - Analyst Consensus Forecast|XRTX - Analyst Consensus Forecast|HIND (ReShape Lifesciences) - Consensus Target|Revelation Biosciences Corp - Fair Value Consensus|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|scinai.com (SCNI) - Analyst Median Target|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGMS: Consensus Target|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|Broker Consensus Forecast TCBP|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
